Table 1.
Characteristics of 1431 gastric cancer patients with signet ring cells
| Characteristics | Overall (n = 1431, %) | Male (n = 935, 65.3%) |
Female (n = 496, 34.7%)
|
P value 1 |
| Age (yr) | ||||
| mean ± SD | 56.3 ± 11.3 | 57.5 ± 10.7 | 54.2 ± 12.1 | < 0.01 |
| < 50 | 386 (27.0) | 213 (55.2) | 173 (44.8) | < 0.01 |
| ≥ 50, < 60 | 444 (31.0) | 303 (68.2) | 141 (31.8) | |
| ≥ 60 | 601 (42.0) | 419 (69.7) | 182 (30.3) | |
| BMI (kg/m2) | ||||
| mean ± SD | 23.8 ± 3.4 | 24.3 ± 3.4 | 22.9 ± 3.3 | < 0.01 |
| > 24 | 659 (46.1) | 501 (76.0) | 158 (24.0) | < 0.01 |
| ≤ 24 | 772 (54.0) | 434 (56.2) | 338 (43.8) | |
| Smoke | < 0.01 | |||
| No | 822 (57.4) | 346 (42.1) | 476 (57.9) | |
| Yes | 609 (42.6) | 589 (96.7) | 20 (3.3) | |
| Drink | < 0.01 | |||
| No | 821 (57.4) | 354 (43.1) | 467 (56.9) | |
| Yes | 610 (42.6) | 581 (95.3) | 29 (4.8) | |
| Tumor site2 | < 0.01 | |||
| Upper | 334 (23.3) | 271 (81.1) | 63 (18.9) | |
| Middle | 345 (24.1) | 205 (59.4) | 140 (40.6) | |
| Lower | 662 (46.3) | 416 (62.8) | 246 (37.2) | |
| Others | 90 (6.3) | 43 (47.8) | 47 (52.2) | |
| Histology differentiation | 0.23 | |||
| Well-/moderately differentiated | 29 (2.1) | 22 (75.9) | 7 (24.1) | |
| Poorly/undifferentiated | 1326 (97.9) | 864 (65.2) | 462 (34.8) | |
| Signet-ring cell proportion (%) | 0.02 | |||
| ≤ 10 | 155 (10.8) | 117 (75.5) | 38 (24.5) | |
| > 10, ≤ 50 | 954 (66.7) | 616 (74.6) | 338 (35.4) | |
| > 50, ≤ 90 | 235 (16.4) | 143 (60.9) | 92 (39.2) | |
| > 90 | 87 (6.1) | 59 (67.8) | 28 (32.2) | |
| Lauren type | < 0.01 | |||
| Intestinal | 73 (5.1) | 61 (83.6) | 12 (16.4) | |
| Diffused | 910 (63.6) | 557 (61.2) | 353 (38.8) | |
| Mixed | 353 (24.7) | 261 (73.9) | 92 (26.1) | |
| Unknown | 95 (6.6) | 56 (59.0) | 39 (41.0) | |
| T stage | 0.02 | |||
| T1 | 411 (28.7) | 246 (59.9) | 165 (40.2) | |
| T2 | 172 (12.0) | 119 (69.2) | 53 (30.8) | |
| T3 | 322 (22.5) | 227 (70.5) | 95 (29.5) | |
| T4 | 526 (36.8) | 343 (65.3) | 183 (34.8) | |
| N stage | 0.54 | |||
| N0 | 573 (40.0) | 365 (63.7) | 208 (36.3) | |
| N1 | 192 (13.4) | 130 (67.7) | 62 (32.3) | |
| N2 | 219 (15.3) | 150 (68.5) | 69 (31.5) | |
| N3 | 447 (31.2) | 290 (64.9) | 157 (35.1) | |
| Metastasis | < 0.01 | |||
| No | 1348 (94.2) | 892 (66.2) | 456 (33.8) | |
| Yes | 83 (5.8) | 43 (51.8) | 40 (48.2) | |
| Adjuvant chemotherapy | 0.51 | |||
| No | 924 (64.6) | 598 (64.7) | 326 (35.3) | |
| Yes | 507 (35.4) | 337 (66.5) | 170 (33.5) | |
| Neoadjuvant chemotherapy | 0.72 | |||
| No | 1315 (91.9) | 861 (65.5) | 454 (34.5) | |
| Yes | 116 (8.1) | 74 (63.8) | 42 (36.2) | |
| Nerve invasion | 0.02 | |||
| No | 313 (21.9) | 184 (58.8) | 129 (41.2) | |
| Yes | 714 (49.9) | 477 (66.8) | 237 (33.2) | |
| Unknown | 404 (28.2) | 274 (67.8) | 130 (32.2) | |
| Lymphovascular invasion | 0.02 | |||
| No | 416 (29.1) | 249 (59.9) | 167 (40.1) | |
| Yes | 554 (38.7) | 373 (67.3) | 181 (32.7) | |
| Unknown | 461 (32.2) | 313 (67.9) | 148 (32.1) | |
| HER-2 | 0.28 | |||
| Negative | 1082 (85.3) | 702 (64.9) | 380 (35.1) | |
| Positive | 187 (14.7) | 129 (69.0) | 58 (31.0) | |
| Lymph nodes removed | < 0.01 | |||
| ≤ 16 | 171 (12.0) | 131 (76.6) | 40 (23.4) | |
| > 16, ≤ 30 | 585 (40.9) | 395 (67.5) | 190 (32.5) | |
| > 30 | 675 (47.2) | 409 (60.6) | 266 (39.7) |
1
The P values for age and BMI (continuous variables) were calculated from Wilcoxon–Mann–Whitney test; The P value for other categorical variables were calculated from χ2 test.
2
Tumor site was divided by upper (cardia, fundus, gastroesophageal junction), middle (body, lesser/greater curvature), lower (antrum, pylorus) and other (gastric remnant, anastomosis, linitis plastica) parts of the stomach.
P < 0.05 indicates statistical significance. Row percentage was reported for the overall sample. BMI: Body mass index; HER-2: Human epidermal growth factor receptor 2.